Trial Profile
A multicenter, open-label study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED).
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Landiolol (Primary)
- Indications Paroxysmal supraventricular tachycardia; Supraventricular tachycardia
- Focus Registrational; Therapeutic Use
- Acronyms LANDI-PED
- Sponsors AOP Orphan Pharmaceuticals AG
- 21 Jul 2023 This trial has been completed in Hungary (Date of the global end of the trial: 31-May-2023), according to the European Clinical Trials Database record.
- 01 Jul 2023 This trial has been completed in Austria, according to the European Clinical Trials Database record.
- 28 Jun 2023 This trial has been completed in Lithuania, according to the European Clinical Trials Database record.